Fisk A, Londono L, Carrera-Justiz S, Buckley G
Can Vet J. 2019; 60(9):976-980.
PMID: 31523085
PMC: 6697008.
DiSogra R
Semin Hear. 2019; 40(2):104-107.
PMID: 31036988
PMC: 6486362.
DOI: 10.1055/s-0039-1684040.
Belai N, Gebrehiwet S, Fitsum Y, Russom M
J Med Case Rep. 2018; 12(1):135.
PMID: 29778098
PMC: 5960497.
DOI: 10.1186/s13256-018-1580-8.
Garinis A, Keefe D, Hunter L, Fitzpatrick D, Putterman D, McMillan G
Ear Hear. 2017; 39(1):69-84.
PMID: 28708814
PMC: 5741529.
DOI: 10.1097/AUD.0000000000000464.
Reavis K, McMillan G, Dille M, Konrad-Martin D
Ear Hear. 2015; 36(5):e251-60.
PMID: 25985018
PMC: 4632966.
DOI: 10.1097/AUD.0000000000000176.
Comparison of the effectiveness of monitoring Cisplatin-induced ototoxicity with extended high-frequency pure-tone audiometry or distortion-product otoacoustic emission.
Yu K, Choi C, An Y, Kwak M, Gong S, Yoon S
Korean J Audiol. 2014; 18(2):58-68.
PMID: 25279227
PMC: 4181054.
DOI: 10.7874/kja.2014.18.2.58.
Ginkgo biloba for tinnitus.
Hilton M, Zimmermann E, Hunt W
Cochrane Database Syst Rev. 2013; (3):CD003852.
PMID: 23543524
PMC: 11669941.
DOI: 10.1002/14651858.CD003852.pub3.
Sound therapy (masking) in the management of tinnitus in adults.
Hobson J, Chisholm E, Refaie A
Cochrane Database Syst Rev. 2012; 11:CD006371.
PMID: 23152235
PMC: 7390392.
DOI: 10.1002/14651858.CD006371.pub3.
Antidepressants for patients with tinnitus.
Baldo P, Doree C, Molin P, McFerran D, Cecco S
Cochrane Database Syst Rev. 2012; (9):CD003853.
PMID: 22972065
PMC: 7156891.
DOI: 10.1002/14651858.CD003853.pub3.
Anticonvulsants for tinnitus.
Hoekstra C, Rynja S, van Zanten G, Rovers M
Cochrane Database Syst Rev. 2011; (7):CD007960.
PMID: 21735419
PMC: 6599822.
DOI: 10.1002/14651858.CD007960.pub2.
Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study.
Dille M, Konrad-Martin D, Gallun F, Helt W, Gordon J, Reavis K
J Am Acad Audiol. 2010; 21(6):409-17.
PMID: 20701838
PMC: 5590654.
DOI: 10.3766/jaaa.21.6.6.
Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis K, McMillan G, Austin D, Gallun F, Fausti S, Gordon J
Ear Hear. 2010; 32(1):61-74.
PMID: 20625302
PMC: 5588870.
DOI: 10.1097/AUD.0b013e3181e8b6a7.
Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D, James K, Gordon J, Reavis K, Phillips D, Bratt G
J Am Acad Audiol. 2010; 21(5):301-14.
PMID: 20569665
PMC: 5588921.
DOI: 10.3766/jaaa.21.5.3.
Tinnitus Retraining Therapy (TRT) for tinnitus.
Phillips J, McFerran D
Cochrane Database Syst Rev. 2010; (3):CD007330.
PMID: 20238353
PMC: 7209976.
DOI: 10.1002/14651858.CD007330.pub2.
High-frequency click-evoked otoacoustic emissions and behavioral thresholds in humans.
Goodman S, Fitzpatrick D, Ellison J, Jesteadt W, Keefe D
J Acoust Soc Am. 2009; 125(2):1014-32.
PMID: 19206876
PMC: 2659524.
DOI: 10.1121/1.3056566.
Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
Mulheran M, Degg C, Burr S, Morgan D, Stableforth D
Antimicrob Agents Chemother. 2001; 45(9):2502-9.
PMID: 11502521
PMC: 90684.
DOI: 10.1128/AAC.45.9.2502-2509.2001.
Drug-induced tinnitus and other hearing disorders.
Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M
Drug Saf. 1996; 14(3):198-212.
PMID: 8934581
DOI: 10.2165/00002018-199614030-00006.
Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.
Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagace J
Antimicrob Agents Chemother. 1994; 38(5):1090-5.
PMID: 8067743
PMC: 188155.
DOI: 10.1128/AAC.38.5.1090.
Experimental, clinical and preventive aspects of ototoxicity.
Chiodo A, Alberti P
Eur Arch Otorhinolaryngol. 1994; 251(7):375-92.
PMID: 7857625
DOI: 10.1007/BF00181963.
Current antibiotic usage II: Aminoglycosides, tetracyclines, erythromycin, vancomycin and sulphonamides.
Merchant S, Vithlani N
Indian J Pediatr. 1986; 53(2):199-213.
PMID: 3744457
DOI: 10.1007/BF02748508.